Cell News and Research

RSS

New type of stem cell in the prostate may be a source for prostate cancer, say researchers

A new type of stem cell discovered in the prostate of adult mice can be a source of prostate cancer, according to a new study by researchers at the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center and NewYork-Presbyterian Hospital.

10 Sep 2009

Brain's SCN is the master clock that synchronizes other biological clocks in the body

Alexis Webb enters a small room at Washington University in St. Louis with walls, floor and ceiling painted dark green, shuts the door, turns off the lights and bends over a microscope in a black box draped with black cloth. Through the microscope, she can see a single nerve cell on a glass cover slip glowing dimly.

10 Sep 2009

Galapagos starts new clinical trial for GLPG0259

Galapagos NV (Euronext: GLPG) announced today that it has initiated a second Phase I clinical trial for GLPG0259, a novel candidate drug being developed for rheumatoid arthritis (RA).

10 Sep 2009

Roche Group and ImmunoCellular Therapeutics sign research agreement regarding ICT-69 antibody

ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced today that it has entered into a research and license option agreement regarding its ICT-69 antibody with Roche Group (SWX: ROG.VX; RO.S, OTCQX: RHHBY), one of the world’s leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics.

10 Sep 2009

Oral GLP-1 Analog approved for human clinical trial

Oramed Pharmaceticals, Inc., a developer of oral drug delivery systems, announced today that it has received approval from the Institutional Review Board (IRB) to commence human clinical trials of an oral GLP-1 Analog.

10 Sep 2009

Merck's GARDASIL receives approval from FDA Advisory Committee

Merck & Co., Inc. announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee agreed that efficacy, immunogenicity and safety data from clinical trials in males support the use of GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] in boys and men 9 through 26 years of age for the prevention of genital warts caused by human papillomavirus (HPV) types 6 and 11.

10 Sep 2009

Promega unveils Maxwell 16 Viral Total Nucleic Acid Purification Kit

Promega announces the release of the Maxwell 16 Viral Total Nucleic Acid Purification Kit which, among other labs, currently serves the OCA Hospital in Mexico for H1N1 clinical research.

10 Sep 2009

Karolinska Development announces formation of Pergamum AB business unit

Karolinska Development (publ) have announced the formation of Pergamum AB, a company that will commercialize its dermatology and wound healing opportunities as associated business units within one company. Karolinska Development has transferred all of its holdings from its five dermatology and wound healing companies to Pergamum AB, owning 64% of the new company.

10 Sep 2009

University of California receives $3.5 million grant from NIDA for AIDS vaccine research

The National Institute on Drug Abuse (NIDA) has awarded a $3.5 million grant for AIDS vaccine research to Phillip Berman, professor and chair of biomolecular engineering at the Jack Baskin School of Engineering at the University of California, Santa Cruz.

9 Sep 2009

Chemgenex completes NDA submission for its omacetaxine mepesuccinate to the FDA

ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today the completion of its New Drug Application (NDA) submission to the U.S. Food & Drug Administration (FDA) for OMAPRO™ (omacetaxine mepesuccinate). OMAPRO™ is being developed for the treatment of patients with chronic myeloid leukemia (CML) who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation.

9 Sep 2009

AOLS to initiate clinical study for testing the efficacy of AEOL 10150

Aeolus Pharmaceuticals, Inc. announced today that it has initiated a study to confirm the efficacy of AEOL 10150 as a countermeasure to nuclear and radiological exposure in non-human primates.

9 Sep 2009

INSPIRE Phase I/IIa study data to be presented at ICAAC

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that data from an interim analysis of its INSPIRE Phase I/IIa study of HIV-infected patients with low CD4 T cell counts treated with a three injection cycle of the Company’s investigative immune-modulator, recombinant human Interleukin-7 (CYT107), will be presented during an oral late breaker session at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), to be held September 12-15, 2009, in San Francisco, CA.

9 Sep 2009

GENova Biotherapeutics discusses its anti-cancer drug development strategy

GENova Biotherapeutics, Inc., ("GENova"), today released important information about its anti-cancer drug development strategy and its unique niche in the drug development industry.

9 Sep 2009

aTyr Pharma expands intellectual property portfolio, receives its fifteenth patent

aTyr Pharma announced today that the US Patent office has issued patent US 7,572,452 B2, titled "Method for Stimulating Wound Healing." aTyr Pharma is the sole assignee of this patent, and Professor Sunghoon Kim, a scientific co-founder of aTyr Pharma, is the inventor.

9 Sep 2009

Neuralstem's patent on neural stem cell transplantation approved

Neuralstem, Inc. today announced that it has received notice of allowance from the United States Patent and Trademark Office (USPTO) for its patent entitled “Transplantation of Human Neural Cells For Treatment Of Neurodegenerative Conditions,” number 11/281,640.

9 Sep 2009

Research study on memory formation and storage process in the human brain

A new study that was carried out at the University of Haifa has identified another component in the chain of actions that take place in the neurons in the process of forming memories. This discovery joins a line of findings from previous studies that together provide a better understanding of the most complex processes in nature - the process of memory formation and storage in the human brain. The new study has been published in the prestigious Journal of Neuroscience.

9 Sep 2009

Bayer submits an IND for its MN-IC antibody-drug conjugate to the FDA

Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it has achieved a milestone under its antibody-drug conjugate (ADC) collaboration with Bayer Schering Pharma AG, Germany. The milestone was triggered by Bayer’s submission of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for MN-IC, an ADC for solid tumors.

9 Sep 2009

ADHC allies with INVENT Pharmaceuticals

Ernest B. Remo, Chairman/CEO of American Diversified Holdings Corporation, announced today that ADHC has entered into a broad strategic alliance with INVENT Pharmaceuticals, Inc.

9 Sep 2009

PacifiCord and Milkalicious to sponsor a debate on pediatric vaccines

Dedicated to serving the private cord blood banking needs of Southern California, PacifiCord (www.pacificord.com) announced they are partnering with Milkalicious, an Aliso Viejo-based breastfeeding boutique and education center, in sponsoring “The Great Vaccine Debate.”

9 Sep 2009

Molecular mechanism responsible for transition of non-invasive breast cancer into invasive disease discovered

Active, but non-invasive breast cancer is set free to roam as invasive breast cancer when an overexpressed protein converts it to a different cell type, scientists at The University of Texas M. D. Anderson Cancer Center report in the Sept. 9 issue of the journal Cancer Cell.

9 Sep 2009